Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Stage-Specific Activity of Pentavalent Antimony against <i>Leishmania donovani</i> Axenic Amastigotes

1 Feb 1999

Abstract excerpt

The standard treatment of human visceral leishmaniasis involves the use of pentavalent antimony (SbV) compounds. In recent years increasing numbers of clinical failures of treatment with SbV have been reported, probably due to the development of parasite resistance to this compound. The mode of action and mechanisms of resistance to SbV have not been fully elucidated. In the present study an axenic amastigote...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Research on Leishmaniasis Studies
Share to Veterinary medicine and infectious diseases

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 9925518
DOI: 10.1128/aac.43.2.278

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Stage-Specific Activity of Pentavalent Antimony against <i>Leishmania donovani</i> Axenic AmastigotesPMID 9925518Read ↗

Novel Intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani.Semantic proximity Read ↗

Efficacy of second line drugs on antimonyl-resistant amastigotes of Leishmania infantum.Semantic proximity Read ↗

Increased metacyclogenesis of antimony-resistant <i>Leishmania donovani</i> clinical linesSemantic proximity Read ↗

Experimental studies on the evolution of antimony-resistant phenotype during the in vitro life cycle of Leishmania infantum: implications for the spread of chemoresistance in endemic areas.Semantic proximity Read ↗

In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization.Semantic proximity Read ↗

In Vitro Reduced Susceptibility to Pentavalent Antimonials of a Leishmania infantum Isolate from a Human Cutaneous Leishmaniasis Case in Central ItalySemantic proximity Read ↗

Metabolic adaptations of Leishmania donovani in relation to differentiation, drug resistance, and drug pressure.Semantic proximity Read ↗

Role of Aquaglyceroporin (AQP1) Gene and Drug Uptake in Antimony-resistant Clinical Isolates of Leishmania donovaniSemantic proximity Read ↗

Resistance of<i>Leishmania donovani</i>to Sodium Stibogluconate Is Related to the Expression of Host and Parasite γ-Glutamylcysteine SynthetaseSemantic proximity Read ↗

Linking In Vitro and In Vivo Survival of Clinical Leishmania donovani StrainsSemantic proximity Read ↗

Multi-drug tolerance in <i>Leishmania</i> persister-like cellsSemantic proximity Read ↗

An axenic amastigote system for drug screeningSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.